Meeting
2018 Gastrointestinal Cancers Symposium
The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.
Authors
Kuo-Hsing Chen
National Taiwan University Hospital Yun-Lin Branch, Huwei Township, Taiwan
Kuo-Hsing Chen , Liang-In Lin , Li-Hui Tseng , Yu-Lin Lin , Jau-Yu Liau , Jia-Huei Tsai , Jin-Tung Liang , Been-Ren Lin , Ann-Lii Cheng , Kun-Huei Yeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 667)
DOI
10.1200/JCO.2018.36.4_suppl.667
Abstract #
667
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
First Author: Jean-Baptiste Bachet
Poster
2016 ASCO Annual Meeting
Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts).
First Author: Krittiya Korphaisarn
Poster
2016 Gastrointestinal Cancers Symposium
![Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in <i>KRAS</i> (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].](https://d201v5jt9ylckg.cloudfront.net/173/10963/120799/120799_poster_pv.jpg)
Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].
First Author: Juan Maurel
Poster
2014 ASCO Annual Meeting
Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer patients.
First Author: Safia El Messaoudi